Home/Store/Medicines from European countries
iMENOR (Methotrexate) 10 mg 10 tablets by Orion Corporation — product pack

iMENOR (Methotrexate) 10 mg 10 tablets

€58
Methotrexate 10 mg, 10 divisible tablets - prescription cytotoxic immunosuppressant (antirheumatic, antipsoriatic, cytostatic)
In stock
Share this product with your friends
ShareSharePin it
iMENOR (Methotrexate) 10 mg 10 tablets
Product Details

iMENOR 10 mg (methotrexate) — 10 divisible tablets

iMENOR 10 mg is a prescription cytotoxic and immunosuppressant medicine in the form of divisible tablets containing methotrexate (as methotrexate disodium). This is a French-market pack of 10 tablets. The marketing-authorisation holder is Orion Corporation (Espoo, Finland) and the tablets are manufactured by Orion Corporation, Orion Pharma (Turku or Salo, Finland); the product is distributed in France by Nordic Pharma, Paris.

Product overview

  • Trade name: iMENOR 10 mg, comprimé sécable (iMENOR)
  • Active ingredient: methotrexate 10 mg per tablet (as methotrexate disodium)
  • Strength: 10 mg
  • Dosage form: yellow, convex, capsule-shaped uncoated divisible tablet engraved «ORN 59» on one side, break line on the other (14 mm × 6 mm)
  • Pack size: box of 10 tablets (PVC/aluminium blister), French CIP 34009 302 666 7 0
  • Marketing-authorisation holder: Orion Corporation, Orionintie 1, FI-02200 Espoo, Finland
  • Manufacturer: Orion Corporation, Orion Pharma, Tengstrominkatu 8, FI-20360 Turku, or Joensuunkatu 7, FI-24100 Salo, Finland
  • Country: France (French-market pack; holder and manufacturer are Finnish)
  • Pharmacotherapeutic group: other immunosuppressant / antimetabolite (antirheumatic, antipsoriatic, cytostatic), ATC code L04AX03
  • Notable excipient: lactose 311.2 mg per tablet (as lactose monohydrate)
  • Dispensing status: prescription only (French list I); cytotoxic medicine — handle with care

What methotrexate is used for

According to the French summary of product characteristics, iMENOR is indicated for: active rheumatoid arthritis in adults; severe, disabling, recalcitrant psoriasis that has not responded adequately to other treatments such as phototherapy, PUVA therapy and retinoids, and severe psoriatic arthritis in adults; and maintenance treatment of acute lymphoblastic leukaemia in adults, adolescents and children from 3 years of age.

How to use

For rheumatic diseases, psoriasis and psoriatic arthritis, methotrexate is taken ONCE A WEEK, on the same day each week. A mistake in the dose can cause serious, potentially fatal adverse reactions. The prescribing doctor sets the day of intake and writes it on the prescription.

  • Usual dose: 7.5–15 mg once weekly, adjusted step by step to the best response, without exceeding a total weekly dose of 25 mg; doses above 20 mg per week are associated with a significant increase in toxicity, in particular bone-marrow depression.
  • A test dose of 2.5–5 mg may be given first to exclude unexpected toxic effects; if the laboratory tests are normal after a week, treatment can start.
  • In maintenance treatment of acute lymphoblastic leukaemia the usual single doses are 20–40 mg/m² of body surface area, normally once weekly, inside complex protocols together with other cytostatic medicines.
  • The tablets are swallowed with water; they carry a break line and can be divided into equal doses. Never increase the dose on your own.

Regular monitoring is mandatory: blood count, liver and kidney tests (weekly during the first weeks, then at the intervals your doctor sets), plus examination of the mouth and throat. Folic or folinic acid may be prescribed to reduce side effects (digestive symptoms, sore mouth, hair loss, raised liver enzymes), but vitamin preparations containing folic acid or folinic acid can also reduce the effect of methotrexate — take them only if your doctor prescribes them.

Possible side effects

Most of the reactions listed below are less frequent and less severe at the low doses used in rheumatology and dermatology than at the high doses used in cancer treatment, but serious reactions can occur even at low doses.

  • Very common: loss of appetite, nausea, vomiting, indigestion, stomach pain, stomatitis (sore mouth and lips), raised liver enzymes.
  • Common: infections; reduced formation of blood cells (leucopenia, anaemia, thrombocytopenia); headache, dizziness, unusual tiredness, drowsiness; lung infection (pneumonia), dry cough; diarrhoea; rash, red patches on the skin, itching; hair loss (alopecia).
  • Uncommon: depression, confusion, convulsions, vertigo; gastrointestinal ulceration and bleeding; liver damage, kidney dysfunction; skin reactions to sunlight; joint or muscle pain, reduced bone density.
  • Rare and very rare: severe infection (sepsis), marked visual disturbances, inflammation of the liver, pancreatitis, severe skin reactions, severe lung reactions such as pneumonitis.

Seek medical help immediately if you develop a fever, a persistent dry cough or breathlessness, black or bloody stools, vomiting of blood, mouth ulcers that do not heal, or any severe skin reaction.

Important precautions

  • Do not take iMENOR if you are allergic to methotrexate or to any of the excipients; if you are breastfeeding (and, for non-oncological indications, if you are pregnant); if you have severe liver or kidney disease; if you have or have had bone-marrow disease or serious blood disorders; if you have an immune-system deficiency, a severe or chronic infection or an immunodeficiency syndrome; if you have inflammation or ulcers of the mouth, ulcers of the stomach or intestine, or alcoholism; or if you have recently been vaccinated with, or are due to receive, a live vaccine.
  • Pregnancy: the pack carries the warning «iMENOR + grossesse = interdit». Methotrexate can cause miscarriage and major birth defects. It must not be used in pregnant women, in adolescent girls, or in women of childbearing potential who do not use effective contraception, and it must be stopped well before a planned pregnancy. Methotrexate can also affect sperm production and is genotoxic: men should avoid conceiving a child or donating sperm during treatment and for at least 3 months after stopping.
  • Tell your doctor before starting if you have or have had liver, kidney or lung problems, long-dormant infections (tuberculosis, hepatitis B or C, shingles), a poor general condition, excess weight, ascites or pleural effusion, diabetes treated with insulin, or if you are dehydrated.
  • Blood counts, liver and kidney function must be monitored regularly; a significant fall in white blood cells or platelets requires immediate withdrawal of the medicine. Any new or worsening shortness of breath must be reported quickly, as lung reactions can occur at any time, even at low doses.
  • Avoid intense sunlight and UV exposure (photosensitivity) and use adequate sun protection; radiation-induced dermatitis or sunburn can flare up again during treatment.
  • Methotrexate interacts with many medicines (NSAIDs, salicylates, trimethoprim, probenecid, certain antibiotics, other cytostatics, some antiepileptics). Always tell your doctor and pharmacist about everything you take, including over-the-counter products, and avoid alcohol.
  • Contains lactose (311.2 mg per tablet): patients with galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
  • Cytotoxic handling: keep the medicine out of the sight and reach of children, preferably in a locked cupboard — accidental ingestion of methotrexate can be fatal in a child. Wash your hands before and after handling, disposable gloves are recommended, and pregnant or breastfeeding women should avoid handling the tablets if possible. Contact of the tablets with skin or mucous membranes must be avoided.
  • Do not drive or operate machinery if you feel dizzy, unusually tired or sleepy.

Storage

Shelf life 3 years. No special storage conditions as regards temperature; keep the blister in the outer carton, protected from light. Do not use after the expiry date shown on the blister and the carton (the last day of that month). Unused medicine and waste must be disposed of in accordance with the rules for cytotoxic agents.

Important notice

The pack photo is shown for identification purposes; packaging design and leaflet language may vary between markets. This text summarises the official French product information (RCP and patient leaflet, ANSM) and is not a substitute for the advice of your doctor or pharmacist. iMENOR is a prescription cytotoxic medicine and must be used only under medical supervision.

📦 Ask about availability and delivery to your country on WhatsApp

Show More
You May Also Like
Lederfolin 15 mg (Leucovorin) 10 tablets
Lederfolin 15 mg (Leucovorin) 10 tablets
Lederfolin 15 mg (Leucovorin) 10 tablets
Oncology
€69
Leucovorin Calcium 15 mg 40 tablets
Leucovorin Calcium 15 mg 40 tablets
Leucovorin Calcium 15 mg 40 tablets
Detoxification
€72
  • My Account
  • Track Orders
  • Shopping Bag
Display prices in:EUR
Skip to main content
APV pharma company
Catalog
Payment and delivery
Contacts
How to place an order
ENRU
Menu
Language:
ENRU
Report Abuse
Powered by Lightspeed